亚太实业(000691) - 2014 Q3 - 季度财报(更新)

Financial Performance - Net profit attributable to shareholders decreased by 1,206.74% to -CNY 2,911,077.04 for the current period[6] - Operating revenue decreased by 37.58% to CNY 4,458,122.00 compared to the same period last year[6] - Basic earnings per share dropped by 1,225.00% to -CNY 0.0090[6] - The company reported a total revenue of CNY 4,458,122.00, down from CNY 7,142,235.00, representing a decline of approximately 37.5% year-over-year[34] - The net profit for the third quarter was a loss of CNY 2,803,090.31, compared to a profit of CNY 502,373.33 in the previous year[35] - The total comprehensive income for the third quarter was a loss of CNY 2,803,090.31, contrasting with a gain of CNY 502,373.33 in the prior year[35] - The company reported a total profit loss of CNY -1,294,375.84 for the quarter, compared to a profit of CNY 3,158,460.73 in the same period last year[40] Assets and Liabilities - Total assets increased by 14.40% to CNY 326,621,068.54 compared to the end of the previous year[6] - Current assets rose to CNY 231,418,891.59, up from CNY 219,454,992.39, indicating an increase of about 5.4%[28] - Non-current assets totaled CNY 95,202,176.95, compared to CNY 66,063,300.05, reflecting a significant increase of approximately 44.1%[29] - Total liabilities increased to CNY 163,339,165.97 from CNY 119,679,311.04, marking a rise of about 36.5%[30] - As of September 30, 2014, accounts payable were ¥11,908,400.24, a decrease of 48.00% from the beginning of the year, mainly due to increased payments for prior project costs.[14] - As of September 30, 2014, other payables were ¥87,902,331.71, an increase of 35% compared to the beginning of the year, primarily due to increased inter-company transactions.[14] Cash Flow - Cash flow from operating activities increased by 101.67% to CNY 4,398,886.37 year-to-date[6] - Operating cash inflow for the current period reached ¥49,717,906.30, an increase of 69.5% compared to ¥29,303,146.80 in the previous period[46] - Net cash flow from operating activities was ¥4,398,886.37, up from ¥2,181,276.78 in the previous period, representing a 101% increase[46] - Cash inflow from investment activities totaled ¥8,750,000.00, with a net cash flow from investment activities of ¥7,801,941.86[47] - Cash outflow from financing activities was ¥5,779,998.00, resulting in a net cash flow from financing activities of -¥5,779,998.00[47] - The net increase in cash and cash equivalents for the current period was ¥6,420,830.23, compared to ¥2,181,276.78 in the previous period[47] Shareholder Information - The total number of common shareholders at the end of the reporting period was 20,233[9] - The top ten shareholders held a combined 27.27% of the total shares, with the largest shareholder owning 9.97%[9] Expenses - Operating costs for the reporting period were ¥2,560,533.49, a decrease of 41.79% compared to the previous year, corresponding to the decrease in operating revenue.[15] - Management expenses for the reporting period were ¥3,259,291.05, an increase of 184.36% compared to the previous year, due to increased audit and assessment costs from the company's targeted issuance and increased management expenses from the newly consolidated subsidiary.[15] - The financial expenses for the reporting period amounted to ¥880,650.57, an increase of 280,085.35% compared to the previous year, primarily due to increased interest expenses from short-term borrowings of the newly consolidated subsidiary, Lanzhou Weici Pharmaceutical Co., Ltd.[16] - Management expenses surged to CNY 6,160,170.25, compared to CNY 2,683,073.04 in the previous year, indicating a significant increase in operational costs[39] Other Financial Metrics - Investment income for the reporting period was -¥35,171.13, a decrease of 55.03% compared to the previous year, mainly due to a decrease in the equity stake held in the joint venture, Jinan Gude Electronic Devices Co., Ltd.[16] - Investment losses amounted to CNY -251,805.54, a significant improvement from CNY -2,037,252.63 in the previous year[39] - The total assets impairment loss was recorded at CNY -593,341.34, indicating ongoing challenges in asset management[43] Operational Highlights - The company has not reported any new product launches or market expansions in the current quarter[51]